Vaxart (NASDAQ:VXRT) Issues Earnings Results

Vaxart (NASDAQ:VXRT) issued its earnings results on Thursday. The biotechnology company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05, Zacks reports. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%. The firm had revenue of $15.19 million for the quarter, compared to analyst estimates of $15.68 million.

Vaxart Stock Performance

Shares of NASDAQ:VXRT opened at $0.52 on Friday. The firm has a market cap of $117.40 million, a PE ratio of -1.26 and a beta of 1.69. The firm’s fifty day moving average is $0.65 and its 200-day moving average is $0.71. Vaxart has a 52 week low of $0.45 and a 52 week high of $1.41.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.